Financial Daily from THE HINDU group of publications
Sunday, May 15, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Alliances & Joint Ventures


Win Medicare-Leo Pharma duo may expand to critical care segment

P.T. Jyothi Datta

Mumbai , May 14

AFTER bringing in a range of skin-related products to treat psoriasis, Win Medicare Pvt Ltd expects to expand the scope of its deal with Denmark-based Leo Pharma to the critical care segment as well.

But this will be only post-2006, after the range of products to treat psoriasis (a chronic skin condition) have been commercialised in India, said Mr Surjit S. Aurora, Vice-President with Win Medicare. "We will look at the critical care segment at products such as heparin, an anticoagulant (used to prevent the formation of blood-clots)," he told Business Line.

Only recently Win Medicare formalised its deal with Leo Pharma for psoriasis and other dermatological conditions. As part of this deal, the company expects to launch Daivonex in the Indian market by September. Other similar products too are slated for the domestic market, including a reputed psoriasis product Daivobet, to be launched in November.

Old therapies used to deal with psoriasis contain steroids and have side-effects. Daivonex, he said contained no steroids and was safe for long-term use.

Leo Pharma is a $800-million company and more than half that revenue comes from the sales of Daivonex and Daivobet. Win Medicare expects Daivonex to clock about Rs 2 crore in its first year after launch. The product expects to touch sales of Rs 10 crore in three years, Mr Aurora said.

Subsequently, Win Medicare would also bring in an opthamologic gel, Fucithalmic, by April next year. Explaining its application, he said that the gel becomes a drop when applied to the eye.

Win Medicare is part of the U.K. Modi Group. The company has a host of marketing alliances with several multinational companies, including Switzerland's Mundi Pharma, Germany's Merz Pharmaceuticals GmbH and IBSA of Switzerland, to name a few. Win Medicare clocked revenues of Rs 120 crore for the year ended December 2004 and expects to end the current year at Rs 145 crore.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
Somany Tiles to market Turkish company products


Pantaloon Retail opens 3 outlets in a single day
Aerens group plans to set up speciality malls
Nava Bharat to consider stock split
AP Paper to pay Rs 2.50/share
PFC sanctions Rs 530 cr for Essar Power project
Merrill Lynch to play major role in Basell acquisition
Siticable acquires RPG's MSO
Win Medicare-Leo Pharma duo may expand to critical care segment
`We notched our highest-ever sales growth in 04'


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line